Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

v3.24.2.u1
Fair Value Measurements (Tables) - Warrants to Purchase Common Stock [Member]
6 Months Ended
Jun. 30, 2024
Schedule of revaluation of warrant liability

Warrants

($ in thousands)

    

liabilities

Balance at December 31, 2023

$

886

Change in fair value of common stock warrants - Avenue

(139)

Change in fair value of common stock warrants - Checkpoint

Change in fair value of placement agent warrants - Urica

(24)

Exercise of common stock warrants - Avenue

(400)

Exchange of common stock warrants - Urica

(151)

Balance at June 30, 2024

$

172

Checkpoint Common Stock Warrants  
Summary of the Weighted average Significant Unobservable Inputs

June 30, 

December 31,

Checkpoint Warrants

2024

2023

Exercise price

$

5.41

$

5.41

Volatility

106.9

%

96.4

%

Expected life in years

3.5

4.0

Risk-free rate

4.5

%

3.8

%

Avenue Therapeutics, Inc [Member]  
Schedule of revaluation of warrant liability

Avenue

Warrant

($ in thousands)

Liability

Avenue common stock warrant liabilities at December 31, 2023

$

586

Exercise of Avenue common warrants

(400)

Change in fair value of common stock warrant liabilities

(139)

Avenue common stock warrant liabilities at June 30, 2024

$

47

Summary of the Weighted average Significant Unobservable Inputs

June 30, 

December 31

2024

2023

Stock price

$ 3.50

$ 12.00

Risk-free interest rate

    

4.52

%  

3.84

%  

Expected dividend yield

 

 

 

Expected term in years

 

3.3

 

3.8

 

Expected volatility

 

160

%  

148

%  

Urica  
Summary of the Weighted average Significant Unobservable Inputs

December 31,

2023

Risk-free interest rate

    

3.93

%  

Expected dividend yield

 

 

Expected term in years

 

0.5

 

Expected volatility

 

153.6

%